DOCSLIB.ORG

Medical Treatment for Idiopathic VT/Vpcs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Treatment for Idiopathic VT/Vpcs APHRS Summit meeting 2016 Medical treatment for idiopathic VT/VPCs Yoshinori Kobayashi MD Tokai university Hachioji hospital Tokyo, JAPAN Classification of idiopathic VT and VPCs according to mechanism and origin of the tachycardia 1) Triggered activity or enhanced automaticity -origin (successful ablation site)- (1) Outflow tract a)RV-Outflow tract (Septum, Free wall, RCC, pulmonary artery) b)LV-Outflow tract (LCC, RCC, Sub-aortic valve endocardium, Cardiac summit) (2) Anterior inflow (His bundle area, NCC) (3) Tricuspid annulus (tricuspid annulus) (4) Mitral annulus (mitral annulus) (5) Papillary muscle (left side dominant, left posterior PM> left anterior PM) (6) His-Purkinje system (Purkinje network, bundle branch) (7) Epicardial LV including cardiac summit (GCV, AIVV, Epicardial approach) (8) Crux (Intra-CS, Mid cardiac vein, Epicardial approach) 2) Reentrant mechanism (1) Verapamil sensitive left ventricular tachycardia (Fascicular tachycardia) a) Posterior type b) Anterior type c) Upper-septal type Delayed afterdepolarization (DADs) in adenosine-sensitive VT Induction of VT during pacing. The small deflection suggesting DADs is noted during pacing on MAP catheter positioned at the site of origin (RVOT). DAD is shown to be facilitated by catecholamine infusion and exercise. VT was terminated by adenosine, and the termination was associated with abolition of DADs Lerman BB et al. Heart Rhythm 2007;4:973-976. Signal transduction schema for initiation and termination of cAMP-mediated triggered activity Vagal maneuvers Adenosine Be-ta blocker Catecholamine Be-ta adrenergic stimulation Exercise and catecholamine increase intracellular cAMP production via stimulation of the Gs protein and induce various cellular responses including acceleration of the L-type calcium channel and Ca release from SR. Then the increase in Ca channel blocker intracellular Ca concentration results in the acceleration of Na-Ca exchanger and Iti, which generates DADs. Adenosine activates the inhibitory Gi protein via adenosine A1 receptor stimulation and antagonize increased cAMP production. Facilitate Lerman BB et al. Heart Rhythm 2007;4:973-976. Suppress Right and left ventricular outflow tract tachycardia Evidence for a common electrophysiologic mechanism Iwai S et al. J Cardiovasc Electrophysiol 2006;17:1052-58 What about the mechanism of idiopathic focal VTs originating in the other regions. LVOT-VTs were similarly shown to be adenosine sensitive and verapamil sensitive. Comparison of clinical parameters between RVOT-VT and LVOT-VT Iwai S et al. J Cardiovasc Electrophysiol 2006;17:1052-58 Autonomic and pharmacological responses of IVT arising from the LVOT 4/5 pts 6/6 pts 4/5 pts Yamawake N et al. J Cardiovasc Electrophysiol 2007;18:1161-66 Location of the origins of annular IVT and induction of VT by exercise Patient population： 9 pts with annular VT Tricuspid annulus:3 Mitral annulus: 7 Epicardial origin:3 Mean VT Cycle length : 450±87 ms 6/6 pts: Programmed pacing initiated VT was initiated by exercise and terminated the VT 7/9 pts: Isoproterenol facilitated initiation of the VT Ip JE et al. Circ Arrhythm Electrophysiol 2014;7:436-444 Response of VT to administration of adenosine, verapamil and Valsalva maneuver Adenosine terminated VT in 9/9 pts Verapamil terminated VT Valsalva maneuvor in 2/2 pts Terminated VT in 2/2 pts Ip JE et al. Circ Arrhythm Electrophysiol 2014;7:436-444 Epicardial origin including the cardiac summit How to measure the MDI Distribution of the origin of epicardial VT/VPC Electrophysiological characteristics: ISP: Facilitate the tachycardia occurrence in 10/10 (100%) Pacing: induced the tachycardia in 8/10 (80%) terminated the tachycardia in 10/10 (100%) Adenosine: terminated VT in 8/9 (89%) Entrainment phenomenon (-) B: Distribution of MDI values Cyclic AMP mediated triggered activity in various subgroups. Daniels DV et al. Circulation 2006;113:1659-1666 Anatomical and ECG characteristics of VAs originating in PM Yamada T et al. Circ Arrhythm Electrophsiol. 2010;3:324-31 Distribution of the origins of PM ventricular arrhythmias and electrophysiological characteristics Electrophysiological features 1) Refractoriness to verapamil and Na channel blockers 2) Tendency for PVCs rather than VT 3) Inducibility with exercise 4) Lack of inducibility with programmed pacing 5) Focal mechanism proved by mapping system (Centrifugal activation pattern) Distribution of origin of Non-reentrant mechanism Triggered activity LV papillary muscle or enhanced automaticity Yamada T et al. JCE. 2009;20:866-72 12.1. Idiopathic Ventricular Tachycardia Recommendations Class I Catheter ablation is useful in patients with structurally normal hearts with symptomatic, drug-refractory VT arising from the RV or LV or in those who are drug intolerant or who do not desire long-term drug therapy. (Level of Evidence: C) Class IIa 1. EP testing is reasonable for diagnostic evaluation in patients with structurally normal hearts with palpitations or suspected outflow tract VT. (Level of Evidence: B) 2. Drug therapy with beta blockers and/or calcium channel blockers (and/or IC agents in RVOT VT) can be useful in patients with structurally normal hearts with symptomatic VT arising from the RV. (Level of Evidence: C) 3. ICD implantation can be effective therapy for the termination of sustained VT in patients with normal or near normal ventricular function and no structural heart disease who are receiving chronic optimal medical therapy and who have reasonable expectation of survival for more than 1 y. (Level of Evidence: C) ACC/AHA/ESC 2006 guidelines foe management of patients with ventricular arrhythmias And the prevention of sudden cardiac death. Circulation 2006;114:e385-484 Previously reported success rate of catheter ablation in various subtypes of idiopathic VT/VPCs RVOT 80-95% LVOT (Endocardial) 70-80% LVOT (Epicardial) 60-80% Near sinus of Valsalva 70-90% Tricuspid or mitral anuli 80-90% LV Papillary muscle 50-70% Cardiac crux 50-80% Fascicular VT (verapamil-sensitive) 90-100% Effect of be-ta blockers on the frequency of VPCs, symptoms and circadian variation Randomized placebo-control study Pre-drug RVOT-VT 25 pts: Atenolol 50-100mg/day 27 pts: placebo group Propranolol attenuated circadian variation of VPCs originating RVOT Post-drug Atenolol significantly reduced PVC count, basic HR and symptoms Krittayaphon R et al. AHJ 2002;144:e15 Hayashi H et al. AJC 1999;84:99 12.1. Idiopathic Ventricular Tachycardia Recommendations Class I Catheter ablation is useful in patients with structurally normal hearts with symptomatic, drug-refractory VT arising from the RV or LV or in those who are drug intolerant or who do not desire long-term drug therapy. (Level of Evidence: C) Class IIa 1. EP testing is reasonable for diagnostic evaluation in patients with structurally normal hearts with palpitations or suspected outflow tract VT. (Level of Evidence: B) 2. Drug therapy with beta blockers and/or calcium channel blockers (and/or IC agents in RVOT VT) can be useful in patients with structurally normal hearts with symptomatic VT arising from the RV. (Level of Evidence: C) 3. ICD implantation can be effective therapy for the termination of sustained VT in patients with normal or near normal ventricular function and no structural heart disease who are receiving chronic optimal medical therapy and who have reasonable expectation of survival for more than 1 y. (Level of Evidence: C) ACC/AHA/ESC 2006 guidelines foe management of patients with ventricular arrhythmias And the prevention of sudden cardiac death. Circulation 2006;114:e385-484 Spatial distribution of Pd potential and Pp potential in 6 patients with ILVT using CARTO 2 specific local potentials can be detected at the left posteroseptal region I I II II V1 V1 40ms MAP * * * MAP * * * Pd potential defined as a slow or fragmented Pp potential defined as spiky potential potential preceding QRS complex preceding QRS complex >40msec >0msec J Arrhythm. 2015; 31(5): 261–267 Schematic presentation of the distribution of Pd and Pp potential Case1 Case2 Case3 RAO view PP PP PP PD PD PD Case4 Case5 Case6 PP PP PP PD PD PD Pd potential Pp potential Pd-Pp fusion potential J Arrhythm. 2015; 31(5): 261–267 Effects of lidocaine and verapamil on the conduction of Pd region Both lidocaine and verapamil prolongs the Pd-Pp interval during the entrainment pacing and the tachycardia. Because both drugs increased the conduction time over the SCZ, the SCZ contains both the depressed sodium- channel-dependent tissue and the calcium channel dependent tissue. Tsuchiya T et al. JACC 2001;37:1415 Pilsicainide-induced verapamil sensitive ILVT At the successful ablation site, both DPs and PPs could be recorded. Because the mechanism of ILVT is reentry with excitable In the baseline study, sustained VT could not be gap, increased conduction delay within the reentry circuit induced by RV programmed pacing, while after by pilsicainide is likely mechanism for the induction and low-dose of pilsicainide it became inducible with perpetuation of the tachycardia. reproducibility. Nagai T et al. PACE 2006;29:549 Summary 1) Idiopathic ventricular arrhythmias (VA:VT/VPC) has a variety of origins which are distributed In both right and left ventricles. 2) The underlying mechanism of most of IVAs except the fascicular VT have been shown to be cAMP-mediated triggered activity (delayed after-depolarization) or enhanced automaticity. 3) Thus, these arrhythmias are supposed to be sensitive to be-ta blockers and calcium channel blockers, and sometimes susceptible to Na channel blockers too. 4) Although the catheter ablation has been shown to be highly effective in suppressing this category of the arrhythmias, the success rate in the IVAs originating in several specific regions such as epicardium and papillary muscles remains relatively low. In such refractory patients to catheter ablation, the role of medical treatment including hybrid therapies still remains as one of therapeutic options. 5)In the patients with fascicular tachycardia (verapamil-sensitive VT), catheter ablation is very effective, therefore the role of the antiarrhythmic therapy is relatively low.
Load more

Recommended publications
  • Uniqueness of Pilsicainide in Class Ic Antiarrhythmics Takeshi
    Uniqueness of Pilsicainide in Class Ic Antiarrhythmics Takeshi YAMASHITA, MD, Yuji MURAKAWA, MD, Kazunori SEZAKI, MD, Noriyuki HAYAMI, MD, Masashi INOUE, MD, Ei-ichi FUKUI, MD, and Masao OMATA, MD SUMMARY Pilsicainide, a class Ic agent, is known to be an effective drug particularly for treating atrial tachyarrhythmias. However, its electrophysiological effects on the atrium have not been well studied. To characterize the electrophysiologic effects of pilsicainide on atrial myocytes in class Ic drugs, we examined the effects of this drug on membrane currents in single rabbit atrial myocytes using the tight-seal whole cell voltage-clamp technique. Under the current-clamp condition, pilsicainide did not affect the action potential duration at therapeutic ranges (3ƒÊM) and slightly shortened it at higher concentrations (10ƒÊM). These observations were quite different from those with other class Ic agents including flecainide and propafenone which prolong the atrial action potential duration. The drug did not affect the resting membrane potential. Under the voltage-clamp condition, pilsicainide inhibited the transient outward current (Ito) that is more prominent in the atrium than in the ventricle in a concentra- tion-dependent manner. However, in contrast to other class Ic agents, the inhibition of Ito by pilsicainide was observed only at much higher concentra- tions (IC50-300ƒÊM) and did not affect the inactivation time-course of Ito. Moreover, the drug (10ƒÊM) did not significantly affect the Ca2+, delayed rec- tifier K+, inward rectifying K+, acetylcholine-induced K+ or ATP-sensitive K+ currents. From these results, pilsicainide could be differentiated as a pure Na+ channel blocker from other class Ic agents with diverse effects on membrane currents and should be recognized accordingly in clinical situations.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • What Is the Diagnosis?
    CLINICAL ARRHYTHMIA https://doi.org/10.24207/jca.v32i2.988_IN Challenge What is the Diagnosis? CASE PRESENTATION A female 82-year-old Caucasian patient with a history of paroxysmal atrial fi brillation (AF) for several years, with palpitation crises of varying duration between a few minutes and several hours, without clinical control, using beta-blockers and diltiazem. Th e patient presented complaints of fatigue on moderate eff orts, without precordial pain or syncope, with progressive asthenia and indisposition. She informed three previous hospitalizations for chemical cardioversion of AF. Th e patient had a history of systemic arterial hypertension, hypothyroidism, and atherosclerotic heart disease, and underwent coronary angioplasty in 2014 with the placement of a nonpharmacological stent, without a prior heart attack. She was on regular use of irbesartan 300 mg, clopidogrel 75 mg, and levothyroxine 75 mcg. Over the past eight months, there has been a worsening of AF crises, and she started to take propafenone in increasing doses, initially 150 mg BID, without improvement of symptoms, then 300 mg BID and currently 750 mg/day (300 – 150 – 300 mg 8/8 hours), without control of palpitations and with feeling of discomfort and weakness. On physical examination, the patient was in good general condition, with no signifi cant abnormalities. Her blood pressure was at 135/80 mmHg, with a heart rate of 72 bpm, irregular rhythm due to the presence of extrasystoles, normophonetic sounds in two times and mild systolic murmur at a mitral focus. Laboratory tests were within normal limits. Th e patient presented Doppler echocardiography with left ventricle (LV) with standard segmental dimensions and contractility, ejection fraction of 68%, slight concentric LV hypertrophy, left atrium with slight increase (44 mm), alteration in LV distensibility, presence of mild mitral valve insuffi ciency and absence of pulmonary arterial hypertension or dilatation of right chambers.
    [Show full text]
  • Ventricular Tachycardia Drugs Versus Devices John Camm St
    Cardiology Update 2015 Davos, Switzerland: 8-12th February 2015 Ventricular Arrhythmias Ventricular Tachycardia Drugs versus Devices John Camm St. George’s University of London, UK Imperial College, London, UK Declaration of Interests Chairman: NICE Guidelines on AF, 2006; ESC Guidelines on Atrial Fibrillation, 2010 and Update, 2012; ACC/AHA/ESC Guidelines on VAs and SCD; 2006; NICE Guidelines on ACS and NSTEMI, 2012; NICE Guidelines on heart failure, 2008; NICE Guidelines on Atrial Fibrillation, 2006; ESC VA and SCD Guidelines, 2015 Steering Committees: multiple trials including novel anticoagulants DSMBs: multiple trials including BEAUTIFUL, SHIFT, SIGNIFY, AVERROES, CASTLE- AF, STAR-AF II, INOVATE, and others Events Committees: one trial of novel oral anticoagulants and multiple trials of miscellaneous agents with CV adverse effects Editorial Role: Editor-in-Chief, EP-Europace and Clinical Cardiology; Editor, European Textbook of Cardiology, European Heart Journal, Electrophysiology of the Heart, and Evidence Based Cardiology Consultant/Advisor/Speaker: Astellas, Astra Zeneca, ChanRX, Gilead, Merck, Menarini, Otsuka, Sanofi, Servier, Xention, Bayer, Boehringer Ingelheim, Bristol- Myers Squibb, Daiichi Sankyo, Pfizer, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Actelion, GlaxoSmithKline, InfoBionic, Incarda, Johnson and Johnson, Mitsubishi, Novartis, Takeda Therapy for Ventricular Tachycardia Medical therapy Antiarrhythmic drugs Autonomic management Ventricular tachycardia Monomorphic Polymorphic Ventricular fibrillation Ventricular storms Ablation therapy Device therapy Surgical Defibrillation Catheter Antitachycardia pacing History of Antiarrhythmic Drugs 1914 - Quinidine 1950 - Lidocaine 1951 - Procainamide 1946 – Digitalis 1956 – Ajmaline 1962 - Verapamil 1962 – Disopyramide 1964 - Propranolol 1967 – Amiodarone 1965 – Bretylium 1972 – Mexiletine 1973 – Aprindine, Tocainide 1969 - Diltiazem 1975- Flecainide 1976 – Propafenone Encainide Ethmozine 2000 - Sotalol D-sotalol 1995 - Ibutilide (US) Recainam 2000 – Dofetilide US) IndecainideX Etc.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Translational Studies on Anti-Atrial Fibrillatory Action of Oseltamivir by Its in Vivo and in Vitro Electropharmacological Analyses
    ORIGINAL RESEARCH published: 29 April 2021 doi: 10.3389/fphar.2021.593021 Translational Studies on Anti-Atrial Fibrillatory Action of Oseltamivir by its in vivo and in vitro Electropharmacological Analyses Ryuichi Kambayashi 1, Hiroko Izumi-Nakaseko 1, Ai Goto 1, Kazuya Tsurudome 2, Hironori Ohshiro 2, Taku Izumi 2, Mihoko Hagiwara-Nagasawa 1, Koki Chiba 1, Ryota Nishiyama 3, Satomi Oyama 3, Yoshio Nunoi 1, Yoshinori Takei 4, Akio Matsumoto 5 and Atsushi Sugiyama 1,4,5,6* 1Department of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan, 2Sophion Bioscience K.K., Saitama, Japan, 3Drug Research Department, TOA EIYO LTD., Fukushima, Japan, 4Department of Translational Research and Cellular Therapeutics, Faculty of Medicine, Toho University, Tokyo, Japan, 5Department of Aging Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan, 6Yamanashi Research Center of Clinical Pharmacology, Yamanashi, Japan Edited by: Oseltamivir has been shown to prolong the atrial conduction time and effective refractory Apostolos Zarros, University of Glasgow, period, and to suppress the onset of burst pacing-induced atrial fibrillation in vitro.Tobetter United Kingdom predict its potential clinical benefit as an anti-atrial fibrillatory drug, we performed translational Reviewed by: studies by assessing in vivo anti-atrial fibrillatory effect along with in vivo and in vitro Ilya Kolb, Janelia Research Campus, electropharmacological analyses. Oseltamivir in intravenous doses of 3 (n 6) and United States 30 mg/kg (n 7) was administered in conscious state to the persistent atrial fibrillation Jordi Heijman, model dogs to confirm its anti-atrial fibrillatory action. The model was prepared by tachypacing Maastricht University, Netherlands > *Correspondence: to the atria of chronic atrioventricular block dogs for 6 weeks.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea
    Original Article Yonsei Med J 2019 Dec;60(12):1157-1163 https://doi.org/10.3349/ymj.2019.60.12.1157 pISSN: 0513-5796 · eISSN: 1976-2437 Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea Min Kim1*, Woojin Kim2*, Changsoo Kim2,3, and Boyoung Joung1 1Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul; 2Department of Preventive Medicine, Yonsei University College of Medicine, Seoul; 3Institute of Human Complexity and Systems Science, Yonsei University, Seoul, Korea. Purpose: Although the economic and mortality burden of atrial fibrillation (AF) is substantial, it remains unclear which treat- ment strategies for rate and rhythm control are most cost-effective. Consequently, economic factors can play an adjunctive role in guiding treatment selection. Materials and Methods: We built a Markov chain Monte Carlo model using the Korean Health Insurance Review & Assessment Service database. Drugs for rate control and rhythm control in AF were analyzed. Cost-effective therapies were selected using a cost-effectiveness ratio, calculated by net cost and quality-adjusted life years (QALY). Results: In the National Health Insurance Service data, 268149 patients with prevalent AF (age ≥18 years) were identified between January 1, 2013 and December 31, 2015. Among them, 212459 and 55690 patients were taking drugs for rate and rhythm control, respectively. Atenolol cost $714/QALY. Among the rate-control medications, the cost of propranolol was lowest at $487/QALY, while that of carvedilol was highest at $1363/QALY. Among the rhythm-control medications, the cost of pilsicainide was lowest at $638/QALY, while that of amiodarone was highest at $986/QALY.
    [Show full text]
  • Drugs to Avoid in Brugada Syndrome Patients January 2015
    Concerns: ______________________ Date of birth: ______________________ Dear colleague, Because of cardiologic and/or genetic evidence of Brugada syndrome in the patient mentioned above, I advised him/her not to take the following prescriptions: DRUGS TO BE AVOIDED Antiarrhythmic drugs*: Ajmaline, Allapinine, Ethacizine, Flecainide, Pilsicainide, Procainamide, Propafenone Psychotropic drugs: Amitriplyline, Clomipramine, Desipramine, Lithium, Loxapine, Nortriptyline, Oxcarbazepine, Trifluoperazine Anesthetics / analgesics*: Bupivacaine, Procaine, Propofol Other substances: Acetylcholine, Alcohol (toxicity), Cannabis, Cocaine, Ergonovine *For advice please visit www.brugadadrugs.org/emergencies DRUGS PREFERABLY AVOIDED Antiarrhythmic drugs: Amiodarone, Cibenzoline, Disopyramide, Lidocaine*, Propranolol, Verapamil, Vernakalant Psychotropic drugs: Bupropion, Carbamazepine, Clothiapine, Cyamemazine, Dosulepine, Doxepine, Fluoxetine, Fluvoxamine, Imipramine, Lamotrigine, Maprotiline, Paroxetine, Perphenazine, Phenytoin, Thioridazine Anesthetics / analgesics: Ketamine, Tramadol Other substances: Demenhydrinate, Diphenhydramine, Edrophonium, Indapamide, Metoclopramide, Terfenadine/Fexofenadine * Lidocaine use for local anesthesia (e.g. by dentists) does seem to be safe if the amount administrated is low and if it is combined with adrenaline (epinephrine) which results in a local effect only. Further, in case of fever, close (electrocardiographic) monitoring is appropriate in combination with lowering of the body temperature (e.g. by using Paracetamol/Acetaminophen).
    [Show full text]
  • Prolonged Atrioventricular Block and Ventricular Standstill Following
    Oe K Prolonged AV block with ATP Case Report Prolonged Atrioventricular Block and Ventricular Standstill Following Adenosine Triphosphate Injection in a Patient Taking Dipyridamole and Antiarrhythmic Agents: A Case Report Kotaro Oe MDÃ1, Tsutomu Araki MDÃ1, Kenshi Hayashi MDÃ2, Masakazu Yamagishi MDÃ2 Ã1Division of Internal Medicine, Saiseikai Kanazawa Hospital Ã2Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine An 83-year-old woman was admitted to our hospital because of palpitation. She had hypertension and paroxysmal atrial fibrillation, treated with digoxin and cibenzoline, and took dipyridamole for microalbuminuria. Before admission, she had taken pilsicainide pills in addition. On admission, electrocardiogram showed regular tachycardia with mildly prolonged QRS width. For the purpose of terminating tachycardia, 10 mg of adenosine triphosphate (ATP) was rapidly injected. About 20 sec later, atrioventricular block and ventricular standstill occurred. She presented loss of consciousness and convulsion, and chest compression was performed. About 30 sec later, the QRS complex reappeared, and she became alert. Serum concentration of digoxin, cibenzoline and pilsicainide was within therapeutic level, respectively. We should be cautious in using ATP for a patient taking dipyridamole and antiarrhythmic agents. (J Arrhythmia 2009; 25: 219–222) Key words: Adenosine, Cardiac arrest, Antiarrhythmia agents Introduction Case Report Adenosine has been commonly used to treat An 83-year-old woman was admitted to our
    [Show full text]
  • ST Segment Elevation in the Right Precordial Leads Following Administration of Class Ic Antiarrhythmic Drugs
    Heart 2001;85:e3 (http://www.heartjnl.com/cgi/content/full/85/1/e3) 1of3 CASE STUDIES Heart: first published as 10.1136/heart.85.1.e3 on 1 January 2001. Downloaded from ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs M Yasuda, Y Nakazato, H Yamashita, G Sekita, Y Kawano, Y Mineda, K Nakazato, T Tokano, M Sumiyoshi, Y Nakata Abstract In 1992, Brugada and Brugada1 reported a Electrocardiographic changes were evalu- study of eight patients with idiopathic ventricu- ated retrospectively in five patients without lar fibrillation who showed ST segment eleva- previous episodes of syncope or ventricular tion in the right precordial lead (the Brugada 2–4 fibrillation who developed abnormal ST syndrome). Recent studies have reported that segment elevation mimicking the Brugada class I antiarrhythmic drugs such as flecainide, syndrome in leads V1–V3 after the admin- procainamide, and ajmaline could unmask ST istration of class Ic antiarrhythmic drugs. segment elevation in patients with “latent” Bru- Pilsicainide (four patients) or flecainide gada syndrome. In addition, we reported the first case5 of a patient who had no previous syn- (one patient) were administered orally for cope or ventricular fibrillation, but who showed the treatment of symptomatic paroxysmal electrocardiographic changes mimicking those atrial fibrillation or premature atrial con- of the Brugada syndrome after administration of tractions. The QRS duration, QTc, and JT a class Ic antiarrhythmic drug. Similar cases intervals on 12 lead surface ECG before were presented by us67and others8–10 in ensuing administration of these drugs were all years. In this article we present five such patients within normal range.
    [Show full text]